Sharing Preclinical Findings of Myeloid-Targeting Therapies in Combination with Immunotherapy to Demonstrate Added Therapeutic Benefit

Time: 5:00 pm
day: Day One


• Stating the goal of deploying myeloid-directed therapy in combination with immunotherapy and sharing mechanistic rationale

• Presenting preclinical and translational findings of combination therapies

• Separating the single agent effect of tumor myeloid therapies to demonstrate added benefit in combination

• Discussing how to combine myeloid therapies with experimental therapies earlier in development, and how to time doses, with myeloid therapies to prime the microenvironment vs. co-administration